| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | antiglobulin antibody | 한글 | 항글로불린항체 |
|---|---|---|---|
| 설명 | 항체에 대한 항체, 즉 특정 항체와 결합할 수 있는 항체. 대개 인간의 항체를 쥐에 주사하여 쥐로 하여금 인간 항체에 대한 항체를 만들게 한다(쥐에 있어서는 인간의 항체도 외부에서 들어온 물질이므로). 이것은 여러 가지 실험에서 인간의 특정항체를 검출하는데 이용한다. |
||
| 영문 | antibody | 한글 | 항체 |
|---|---|---|---|
| 설명 | 사람의 몸에서 면역에 관계하는 물질. 외부에서 들어온 물질과 꼭 맞게 결합을 하여서 그 물질의 생물학적 활동을 억제하거나 파괴하거나 사람의 다른 면역세포로 하여금 공격하기 용이하게 해주는 기능을 가지고 있다. 항체는 면역글로부린이라는 것으로 이루어져 있고 그 형태에 따라 IgA, IgE, IgG, IgD등으로 나눈다. |
||
| 영문 | thyroid gland | 한글 | 갑상샘 |
|---|---|---|---|
| 설명 | 사람의 몸에서 가장 큰 내분비샘으로 목의 앞쪽, 아래쪽에 위치하고 있으며 2엽으로 구성되어 있다. 각 엽은 기관의 양쪽에 있으며 좁은 잘룩에 의해 앞에서 연결되어 있다. 갑상샘호르몬인 티록신(thyroxine)을 분비하고 저장하며, 필요에 따라 방출한다. 또한 갑상샘은 티로칼시토닌(thyrocalcitonin)도 분비한다. 병적인 상태에서 크기가 대개 증가하고, 일부에서는 도리어 위축되며, 통증을 나타내기도 한다. |
||
| 영문 | thyroid carcinoma | 한글 | 갑상샘암종 |
|---|---|---|---|
| 설명 | 갑상샘에 생긴 상피세포로 이루어진 악성종양물. 병리조직학적인 형태에 따라 유두상, 소포상, 역형암종 및 수질암종, 림프종 등으로 나눌 수 있다. 다양한 원인이 있으나, 일부에서는 방사선폭로에 의해 발생한다. 치료는 수술, 방사성 옥소, T4 억제요법 등이 사용된다. |
||
| TA | alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t... |
|---|---|
| ACA | abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino... |
| ATA | alimentary toxic aleukia; American Thyroid Association; aminotriazole; antithymic activity; antithyr... |
| AMA | against medical advice; alkaline membrane assay; American Management Association; American Medical A... |
| NA | Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida... |
| TSAb | Thyroid Stimulating Antibody |
|---|---|
| TSBAb | Thyroid stimulation-blocking antibody |
| T3R | 1-thyroid hormone receptor |
| TRbeta | Thyroid hormone receptor beta |
| TR alpha | thyroid hormone receptor alpha |
| thyroid receptor antibody | A test that measures the amount of an antibody (thyroid stimulating antibody) which is directed against a receptor for TSH on the thyroid gland. This antibody acts like TSH and stimulates the thyroid to produce excessive amounts of thyroid hormone. The presence of this antibody generally indicates Grave's disease (hyperthyroidism). (27 Sep 1997) |
|---|
| thyroid stimulating antibody | <endocrinology, immunology> Long acting thyroid stimulator is an autoantibody found in many cases of primary thyrotoxicosis which causes hyperplasia of the thyroid by undetermined mechanisms. Human thyroid stimulating immunoglobulin is a different antibody found in all or nearly all cases of primary thyrotoxicosis and may act by binding to the thyrotropin (TSH) receptor site, causing increased synthesis of thyroglobulin. (18 Nov 1997) |
|---|---|
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
| auditory receptor cells | Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends. See: Corti's cells. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor kinase | <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor Registry number: EC 2.7.1.- Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2 (26 Jun 1999) |
| cAMP receptor protein | catabolite (gene) activator protein |
| GABA receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| p60 tumour necrosis factor receptor-associated kinase | <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor Registry number: EC 2.7.10.- Synonym: p60 tnf receptor-associated kinase, p60-trak (26 Jun 1999) |
| gamma aminobutyric acid receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| GAP-1 receptor tyrosine kinase | <enzyme> Similar to rasGTPase-activating proteins; inhibits signaling activity of let-60; amino acid sequence given in first source Registry number: EC 2.7.1.- Synonym: gap-1 gene product, gap-1 protein (26 Jun 1999) |
| gene rearrangement, alpha-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|